

**Update on Treatments for the Non-Motor Symptoms of Parkinson's Disease –
an Evidence-Based Medicine Review**

References

1. Goetz C, Koller W, Poewe W. Management of Parkinson's disease: an evidence-based review. *Movement disorders : official journal of the Movement Disorder Society* 2002;17 Suppl 4:S1-166.
2. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2011;26 Suppl 3:S42-80.
3. Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2010;35:881-892.
4. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2011;26 Suppl 3:S2-41.
5. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2018.
6. Dixon RA, Munro JF, Silcocks PB. *The evidence based medicine workbook : critical appraisal for clinical problem solving*. Oxford: Butterworth-Heinemann, 1997.
7. Weintraub D, Hauser RA, Elm JJ, et al. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. *Movement disorders : official journal of the Movement Disorder Society* 2016;31:709-714.
8. Papay K, Xie SX, Stern M, et al. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. *Neurology* 2014;83:826-833.
9. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. *Neurology* 2012;78:1229-1236.
10. Bernard BA, Metman LV, Levine L, Ouyang B, Leurgans S, Goetz CG. Sildenafil in the Treatment of Erectile Dysfunction in Parkinson's Disease. *Movement Disorders Clinical Practice* 2017;4:412-415.
11. Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. *The American journal of psychiatry* 2011;168:1066-1074.
12. Ondo WG, Kenney C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. *Neurology* 2012;78:1650-1654.
13. Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. *Movement disorders : official journal of the Movement Disorder Society* 2012;27:219-226.
14. Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. *Movement disorders : official journal of the Movement Disorder Society* 2012;27:1230-1238.
15. Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. *Neurology* 2012;79:651-658.
16. Barone P, Santangelo G, Morgante L, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients. *European journal of neurology* 2015;22:1184-1191.
17. Brys M, Fox MD, Agarwal S, et al. Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: A randomized trial. *Neurology* 2016;87:1907-1915.
18. Makkos A, Pal E, Aschermann Z, et al. High-Frequency Repetitive Transcranial Magnetic Stimulation Can Improve Depression in Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study. *Neuropsychobiology* 2016;73:169-177.

19. Chung SJ, Asgharnejad M, Bauer L, Ramirez F, Jeon B. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease. *Expert opinion on pharmacotherapy* 2016;17:1453-1461.
20. Pierantozzi M, Placidi F, Liguori C, et al. Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. *Sleep Med* 2016;21:140-144.
21. Devos D, Moreau C, Maltete D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. *Journal of neurology, neurosurgery, and psychiatry* 2014;85:668-674.
22. Thobois S, Lhomme E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with pramipexole. *Brain : a journal of neurology* 2013;136:1568-1577.
23. Hauser RA, Slawek J, Barone P, et al. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease. *BMC neurology* 2016;16:90.
24. Lim TT, Kluger BM, Rodriguez RL, et al. Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2015;30:1825-1830.
25. Kluger BM, Rakowski D, Christian M, et al. Randomized, Controlled Trial of Acupuncture for Fatigue in Parkinson's Disease. *Movement disorders : official journal of the Movement Disorder Society* 2016;31:1027-1032.
26. Trenkwalder C, Chaudhuri KR, Martinez-Martin P, et al. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. *The Lancet Neurology* 2015;14:1161-1170.
27. Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). *Journal of Parkinson's disease* 2014;4:57-65.
28. Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). *Movement disorders : official journal of the Movement Disorder Society* 2015;30:646-654.
29. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. *Lancet* 2014;383:533-540.
30. Rascol O, Zesiewicz T, Chaudhuri KR, et al. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain. *Journal of clinical pharmacology* 2016;56:852-861.
31. Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. *Neurology* 2013;80:792-799.
32. Emre M, Poewe W, De Deyn PP, et al. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study. *Clinical neuropharmacology* 2014;37:9-16.
33. Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. *Movement disorders : official journal of the Movement Disorder Society* 2011;26:1851-1858.
34. Biundo R, Weis L, Fiorenzato E, et al. Double-blind Randomized Trial of tDCS Versus Sham in Parkinson Patients With Mild Cognitive Impairment Receiving Cognitive Training. *Brain stimulation* 2015;8:1223-1225.
35. Cerasa A, Gioia MC, Salsone M, et al. Neurofunctional correlates of attention rehabilitation in Parkinson's disease: an explorative study. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology* 2014;35:1173-1180.
36. Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. *Movement disorders : official journal of the Movement Disorder Society* 2015;30:912-918.

37. Nichols MJ, Hartlein JM, Eicken MG, Racette BA, Black KJ. A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease. *F1000Research* 2013;2:150.
38. Zesiewicz TA, Evatt M, Vaughan CP, et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. *Parkinsonism & related disorders* 2015;21:514-520.
39. McClurg D, Walker K, Aitchison P, et al. Abdominal Massage for the Relief of Constipation in People with Parkinson's: A Qualitative Study. *Parkinson's disease* 2016;2016:4842090.
40. Barichella M, Pacchetti C, Bolliri C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT. *Neurology* 2016;87:1274-1280.
41. Eggert K, Ohlwein C, Kassubek J, et al. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. *Clinical neuropharmacology* 2014;37:116-122.
42. Neikrug AB, Liu L, Avanzino JA, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. *Sleep* 2014;37:177-185.
43. Troeung L, Egan SJ, Gasson N. A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson's disease. *BMC psychiatry* 2014;14:19.
44. Calleo JS, Amspoker AB, Sarwar AI, et al. A Pilot Study of a Cognitive-Behavioral Treatment for Anxiety and Depression in Patients With Parkinson Disease. *Journal of geriatric psychiatry and neurology* 2015;28:210-217.
45. Kehagia AA, Housden CR, Regenthal R, et al. Targeting impulsivity in Parkinson's disease using atomoxetine. *Brain : a journal of neurology* 2014;137:1986-1997.
46. Pompeu JE, Mendes FA, Silva KG, et al. Effect of Nintendo Wii-based motor and cognitive training on activities of daily living in patients with Parkinson's disease: a randomised clinical trial. *Physiotherapy* 2012;98:196-204.
47. Witt K, Granert O, Daniels C, et al. Relation of lead trajectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson's disease: results from a randomized trial. *Brain : a journal of neurology* 2013;136:2109-2119.
48. Ricciardi L, De Nigris F, Specchia A, Fasano A. Homotaurine in Parkinson's disease. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology* 2015;36:1581-1587.
49. Pintor L, Valdeoriola F, Bailles E, Marti MJ, Muniz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. *Clinical neuropharmacology* 2012;35:61-66.
50. Perissinotto MC, D'Ancona CA, Lucio A, Campos RM, Abreu A. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with Parkinson disease: a randomized controlled trial. *Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society* 2015;42:94-99.
51. Di Giacomo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2012;27:559-561.
52. Guidubaldi A, Fasano A, Ialongo T, et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2011;26:313-319.
53. Arai E, Arai M, Uchiyama T, et al. Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease. *Brain : a journal of neurology* 2012;135:1478-1485.
54. Wailke S, Herzog J, Witt K, Deuschl G, Volkmann J. Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease. *European journal of neurology* 2011;18:590-596.

55. Korchounov A, Winter Y, Rossy W. Combined beneficial effect of rasagiline on motor function and depression in de novo PD. *Clinical neuropharmacology* 2012;35:121-124.
56. Hauser RA, Isaacson S, Clinch T, Tigan/Apokyn Study I. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. *Parkinsonism & related disorders* 2014;20:1171-1176.
57. Fanciulli A, Goebel G, Metzler B, et al. Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease. *Movement Disorders Clinical Practice* 2016;3:156-160.
58. Lawson RA, Millar D, Brown RG, Burn DJ. Guided self-help for the management of worry in Parkinson's disease: a pilot study. *Journal of Parkinson's disease* 2013;3:61-68.
59. Petrelli A, Kaesberg S, Barbe MT, et al. Effects of cognitive training in Parkinson's disease: a randomized controlled trial. *Parkinsonism & related disorders* 2014;20:1196-1202.
60. Teixeira-Machado L, Araujo FM, Cunha FA, Menezes M, Menezes T, Melo DeSantana J. Feldenkrais method-based exercise improves quality of life in individuals with Parkinson's disease: a controlled, randomized clinical trial. *Alternative therapies in health and medicine* 2015;21:8-14.
61. Lee NY, Lee DK, Song HS. Effect of virtual reality dance exercise on the balance, activities of daily living, and depressive disorder status of Parkinson's disease patients. *Journal of physical therapy science* 2015;27:145-147.
62. Okun MS, Wu SS, Fayad S, et al. Acute and Chronic Mood and Apathy Outcomes from a randomized study of unilateral STN and GPi DBS. *PLoS one* 2014;9:e114140.
63. Hadinia A, Meyer A, Bruegger V, et al. Cognitive Behavioral Group Therapy Reduces Stress and Improves the Quality of Life in Patients with Parkinson's Disease. *Frontiers in psychology* 2016;7:1975.
64. Hashimoto H, Takabatake S, Miyaguchi H, Nakanishi H, Naitou Y. Effects of dance on motor functions, cognitive functions, and mental symptoms of Parkinson's disease: a quasi-randomized pilot trial. *Complementary therapies in medicine* 2015;23:210-219.
65. Frakey LL, Friedman JH. Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia. *The Journal of neuropsychiatry and clinical neurosciences* 2017;29:22-25.
66. Manenti R, Brambilla M, Benussi A, et al. Mild cognitive impairment in Parkinson's disease is improved by transcranial direct current stimulation combined with physical therapy. *Movement disorders : official journal of the Movement Disorder Society* 2016;31:715-724.
67. Cash TV, Lageman SK. Randomized controlled expressive writing pilot in individuals with Parkinson's disease and their caregivers. *BMC psychology* 2015;3:44.
68. Edwards JD, Hauser RA, O'Connor ML, Valdes EG, Zesiewicz TA, Uc EY. Randomized trial of cognitive speed of processing training in Parkinson disease. *Neurology* 2013;81:1284-1290.
69. Zimmermann R, Gschwandtner U, Benz N, et al. Cognitive training in Parkinson disease: cognition-specific vs nonspecific computer training. *Neurology* 2014;82:1219-1226.
70. Paris AP, Saleta HG, de la Cruz Crespo Maraver M, et al. Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2011;26:1251-1258.
71. Pena J, Ibarretxe-Bilbao N, Garcia-Gorostiaga I, Gomez-Beldarrain MA, Diez-Cirarda M, Ojeda N. Improving functional disability and cognition in Parkinson disease: randomized controlled trial. *Neurology* 2014;83:2167-2174.
72. Doruk D, Gray Z, Bravo GL, Pascual-Leone A, Fregni F. Effects of tDCS on executive function in Parkinson's disease. *Neuroscience letters* 2014;582:27-31.
73. Cugusi L, Solla P, Serpe R, et al. Effects of a Nordic Walking program on motor and non-motor symptoms, functional performance and body composition in patients with Parkinson's disease. *NeuroRehabilitation* 2015;37:245-254.
74. Wang F, Sun L, Zhang XZ, et al. Effect and Potential Mechanism of Electroacupuncture Add-On Treatment in Patients with Parkinson's Disease. *Evidence-based complementary and alternative medicine : eCAM* 2015;2015:692795.

75. Ondo WG, Shinawi L, Davidson A, Lai D. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. *Parkinsonism & related disorders* 2011;17:156-159.
76. Jang W, Park J, Shin KJ, et al. Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson's disease. *Journal of the neurological sciences* 2014;337:47-54.
77. Pan W, Liu Y, Fang Z, et al. A compound belonging to traditional Chinese medicine improves nocturnal activity in Parkinson's disease. *Sleep Med* 2011;12:307-308.
78. Shill HA, Obradov S, Katsnelson Y, Pizinger R. A randomized, double-blind trial of transcranial electrostimulation in early Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2011;26:1477-1480.
79. Winward C, Sackley C, Meek C, et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2012;27:143-146.
80. Antonini A, Bauer L, Dohin E, et al. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. *European journal of neurology* 2015;22:1400-1407.
81. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet* 2018;391:1357-1366.
82. Menza M, Dobkin R, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. *Neurology* 2009;72:886-892.
83. George MS, Taylor JJ, Short EB. The expanding evidence base for rTMS treatment of depression. *Curr Opin Psychiatry* 2013;26:13-18.
84. Lee JC, Blumberger DM, Fitzgerald PB, Daskalakis ZJ, Levinson AJ. The role of transcranial magnetic stimulation in treatment-resistant depression: a review. *Curr Pharm Des* 2012;18:5846-5852.
85. Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. *BMC Fam Pract* 2012;13:40.
86. Peterson AL, Roache JD, Raj J, Young-McCaughan S, Consortium SS. The need for expanded monitoring of adverse events in behavioral health clinical trials. *Contemp Clin Trials* 2013;34:152-154.
87. Wang H-F, Yu J-T, Tang S-W, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. *Journal of Neurology, Neurosurgery & Psychiatry* 2015;86:135-143.
88. Nikolin S, Huggins C, Martin D, Alonzo A, Loo CK. Safety of repeated sessions of transcranial direct current stimulation: A systematic review. *Brain stimulation* 2018;11:278-288.
89. Sherman DS, Mauser J, Nuno M, Sherzai D. The Efficacy of Cognitive Intervention in Mild Cognitive Impairment (MCI): a Meta-Analysis of Outcomes on Neuropsychological Measures. *Neuropsychology review* 2017;27:440-484.
90. Webster P. Pimavanserin evaluated by the FDA. *Lancet* 2018;391:1762.
91. (FDA) UFaDA. FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson's disease psychosis. 2018; <https://www.fda.gov/Drugs/DrugSafety/ucm621160.htm> Last accessed: 8 October 2018.
92. Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. *The American journal of psychiatry* 2012;169:900-906.
93. Postuma RB, Berg D, Adler CH, et al. The new definition and diagnostic criteria of Parkinson's disease. *The Lancet Neurology* 2016;15:546-548.

94. Rodrigues TM, Castro Caldas A, Ferreira JJ. Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease: Systematic review and meta-analysis. *Parkinsonism & related disorders* 2016;27:25-34.
95. Kunisaki KM, Khalil W, Koffel E, et al. In: *The Comparative Effectiveness, Harms, and Cost of Care Models for the Evaluation and Treatment of Obstructive Sleep Apnea (OSA): A Systematic Review*. Washington (DC), 2016.
96. Leelakanok N, Holcombe A, Schweizer ML. Domperidone and Risk of Ventricular Arrhythmia and Cardiac Death: A Systematic Review and Meta-analysis. *Clinical drug investigation* 2016;36:97-107.
97. White WB, Hauser RA, Rowse GJ, Ziemann A, Hewitt LA. Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. *Am J Cardiol* 2017;119:1111-1115.
98. FDA. NORTHERA prescribing information. 2017; https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203202s007lbl.pdf Last accessed: 06/22/2018.
99. Luo D, Liu L, Han P, Wei Q, Shen H. Solifenacin for overactive bladder: a systematic review and meta-analysis. *International urogynecology journal* 2012;23:983-991.
100. Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. *The Cochrane database of systematic reviews* 2012;1:CD005429.
101. Vouri SM, Kebodeaux CD, Stranges PM, Teshome BF. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis. *Archives of gerontology and geriatrics* 2017;69:77-96.
102. A. BB, Metman LV, Levine L, Ouyang B, Leurgans S, Goetz CG. Sildenafil in the Treatment of Erectile Dysfunction in Parkinson's Disease. *Mov Dis in Clin Prac* 2016;Vol 4:412-415.
103. Yafi FA, Sharlip ID, Becher EF. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction. *Sexual medicine reviews* 2018;6:242-252.
104. Lloret SP, Nano G, Carrosella A, Gamzu E, Merello M. A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. *Journal of the neurological sciences* 2011;310:248-250.
105. Chen HL, Wu CC, Lin AC. Small bowel intramural hematoma secondary to abdominal massage. *The American journal of emergency medicine* 2013;31:758 e753-754.
106. Li F, Fu T, Tong WD, et al. Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Mayo Clin Proc* 2016;91:456-468.
107. Christie J, Shroff S, Shahnavaz N, et al. A Randomized, Double-Blind, Placebo-Controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients. *Am J Gastroenterol* 2017;112:356-364.
108. McClurg D, Lowe-Strong A. Does abdominal massage relieve constipation? *Nurs Times* 2011;107:20-22.
109. Zweifel N, Meuli M, Subotic U, Moehrlen U, Mazzone L, Arlettaz R. Manufactured volvulus. *European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery [et al] = Zeitschrift fur Kinderchirurgie* 2013;23:234-237.
110. Tak S, Tak S, Gupta A. Peripheral embolisation after an abdominal massage. *BMJ case reports* 2014;2014.
111. Liu H, Chen L, Zhang Z, et al. Effectiveness and safety of acupuncture combined with Madopar for Parkinson's disease: a systematic review with meta-analysis. *Acupunct Med* 2017;35:404-412.
112. Morlion BJ, Mueller-Lissner SA, Vellucci R, et al. Oral Prolonged-Release Oxycodone/Naloxone for Managing Pain and Opioid-Induced Constipation: A Review of the Evidence. *Pain practice : the official journal of World Institute of Pain* 2017.

113. Kim ES. Oxycodone/Naloxone Prolonged Release: A Review in Severe Chronic Pain. *Clinical drug investigation* 2017;37:1191-1201.
114. Guerriero F, Roberto A, Greco MT, Sgarlata C, Rollone M, Corli O. Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study. *Drug Des Devel Ther* 2016;10:1515-1523.
115. Thakur D, Dickerson S, Kumar Bhutani M, Junor R. Impact of prolonged-release oxycodone/naloxone on outcomes affecting patients' daily functioning in comparison with extended-release tapentadol: a systematic review. *Clin Ther* 2015;37:212-224.
116. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. *Movement disorders : official journal of the Movement Disorder Society* 2010;25:704-709.
117. Marin C, Vilas D, Langdon C, et al. Olfactory Dysfunction in Neurodegenerative Diseases. *Curr Allergy Asthma Rep* 2018;18:42.
118. Doty RL. Olfaction in Parkinson's disease and related disorders. *Neurobiol Dis* 2012;46:527-552.
119. Ekker MS, Janssen S, Seppi K, et al. Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked. *Parkinsonism & related disorders* 2017;40:1-10.
120. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. *Nat Rev Dis Primers* 2017;3:17013.
121. Schaeffer E, Berg D. Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease. *CNS Drugs* 2017;31:551-570.
122. Gallagher DA, Schrag A. Psychosis, apathy, depression and anxiety in Parkinson's disease. *Neurobiol Dis* 2012;46:581-589.
123. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Recognition and treatment of depression in Parkinson's disease. *Journal of geriatric psychiatry and neurology* 2003;16:178-183.
124. Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson's disease. *Parkinson Study Group. Neurology* 1997;49:1168-1170.
125. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. *The Lancet Neurology* 2010;9:573-580.
126. Oehlberg K, Barg FK, Brown GK, Taraborelli D, Stern MB, Weintraub D. Attitudes regarding the etiology and treatment of depression in Parkinson's disease: a qualitative study. *Journal of geriatric psychiatry and neurology* 2008;21:123-132.
127. Lesenskyj AM, Samples MP, Farmer JM, Maxwell CR. Treating refractory depression in Parkinson's disease: a meta-analysis of transcranial magnetic stimulation. *Transl Neurodegener* 2018;7:8.
128. Sako W, Miyazaki Y, Izumi Y, Kaji R. Which target is best for patients with Parkinson's disease? A meta-analysis of pallidal and subthalamic stimulation. *Journal of neurology, neurosurgery, and psychiatry* 2014;85:982-986.
129. Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. *The Lancet Neurology* 2015;14:518-531.
130. Castrioto A, Thobois S, Carnicella S, Maillet A, Krack P. Emotional manifestations of PD: Neurobiological basis. *Movement disorders : official journal of the Movement Disorder Society* 2016;31:1103-1113.
131. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B. Motivation, reward, and Parkinson's disease: influence of dopatherapy. *Neuropsychologia* 2002;40:2257-2267.
132. Czernecki V, Schupbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. *Movement disorders : official journal of the Movement Disorder Society* 2008;23:964-969.

133. Wang H-F, Yu J-T, Tang S-W, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. *Journal of Neurology, Neurosurgery & Psychiatry* 2015;86:135.
134. Tricco AC, Soobiah C, Berliner S, et al. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. *CMAJ* 2013;185:1393-1401.
135. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. *JAMA* 2009;301:63-73.
136. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. *N Engl J Med* 2013;368:610-622.
137. Uc EY, Doerschug KC, Magnotta V, et al. Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting. *Neurology* 2014;83:413-425.
138. Leung IH, Walton CC, Hallock H, Lewis SJ, Valenzuela M, Lampit A. Cognitive training in Parkinson disease: A systematic review and meta-analysis. *Neurology* 2015;85:1843-1851.
139. Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. *Journal of neurology, neurosurgery, and psychiatry* 2010;81:160-165.
140. Poewe W. Psychosis in Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2003;18 Suppl 6:S80-87.
141. Poewe W, Seppi K. Treatment options for depression and psychosis in Parkinson's disease. *J Neurol* 2001;248 Suppl 3:III12-21.
142. Hawkins T, Berman BD. Pimavanserin: A novel therapeutic option for Parkinson disease psychosis. *Neurol Clin Pract* 2017;7:157-162.
143. Weintraub D, Chiang C, Kim HM, et al. Antipsychotic Use and Physical Morbidity in Parkinson Disease. *Am J Geriatr Psychiatry* 2017;25:697-705.
144. Weintraub D, Chiang C, Kim HM, et al. Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. *JAMA Neurol* 2016;73:535-541.
145. Moreno GM, Gandhi R, Lessig SL, Wright B, Litvan I, Nahab FB. Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine. *Neurology* 2018.
146. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2006;21:1899-1907.
147. Lim SY, Evans AH, Miyasaki JM. Impulse control and related disorders in Parkinson's disease: review. *Ann N Y Acad Sci* 2008;1142:85-107.
148. Lim SY, Tan ZK, Ngam PI, et al. Impulsive-compulsive behaviors are common in Asian Parkinson's disease patients: assessment using the QUIP. *Parkinsonism & related disorders* 2011;17:761-764.
149. Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2013;28:327-333.
150. Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2015;30:121-127.
151. Pondal M, Marras C, Miyasaki J, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. *Journal of neurology, neurosurgery, and psychiatry* 2013;84:130-135.
152. Patel S, Garcia X, Mohammad ME, et al. Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center. *Journal of the neurological sciences* 2017;379:308-311.
153. Lhomme E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. *Brain : a journal of neurology* 2012;135:1463-1477.

154. Kasemsuk C, Oyama G, Hattori N. Management of impulse control disorders with deep brain stimulation: A double-edged sword. *Journal of the neurological sciences* 2017;374:63-68.
155. Chou KL, Evatt M, Hinson V, Kompoliti K. Sialorrhea in Parkinson's disease: a review. *Movement disorders : official journal of the Movement Disorder Society* 2007;22:2306-2313.
156. Egevad G, Petkova VY, Vilholm OJ. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin. *Journal of Parkinson's disease* 2014;4:321-326.
157. Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. *Movement disorders : official journal of the Movement Disorder Society* 2018;33:372-390.
158. Eschlbock S, Wenning G, Fanciulli A. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. *J Neural Transm (Vienna)* 2017;124:1567-1605.
159. O'Sullivan JD, Hughes AJ. Apomorphine-induced penile erections in Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 1998;13:536-539.
160. Arnold G, Schwarz J, Macher C, Oertel WH. Domperidone is superior to ondansetron in acute apomorphine challenge in previously untreated parkinsonian patients - A double blind study. *Parkinsonism & related disorders* 1997;3:191-193.
161. Rossi M, Merello M, Perez-Lloret S. Management of constipation in Parkinson's disease. *Expert opinion on pharmacotherapy* 2015;16:547-557.
162. Mahowald MW, Schenck CH, Bornemann MA. Pathophysiologic mechanisms in REM sleep behavior disorder. *Curr Neurol Neurosci Rep* 2007;7:167-172.
163. St Louis EK, Boeve AR, Boeve BF. REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies. *Movement disorders : official journal of the Movement Disorder Society* 2017;32:645-658.
164. Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2015;30:510-516.
165. DiMarzio M, Pilitsis JG, Gee L, et al. King's Parkinson's Disease Pain Scale for Assessment of Pain Relief Following Deep Brain Stimulation for Parkinson's Disease. *Neuromodulation* 2018.
166. Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. *Mayo Clin Proc* 2015;90:532-545.
167. Titova N, Padmakumar C, Lewis SJG, Chaudhuri KR. Parkinson's: a syndrome rather than a disease? *J Neural Transm (Vienna)* 2017;124:907-914.
168. Chaudhuri KR, Sauerbier A, Rojo JM, et al. The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system. *Parkinsonism & related disorders* 2015;21:287-291.
169. Titova N, Chaudhuri KR. Non-motor Parkinson disease: new concepts and personalised management. *Med J Aust* 2018;208:404-409.
170. Chaudhuri R, Rojo JM, Schapira AH, et al. A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. *PLoS one* 2013;8:e57221.
171. Poewe W, Hauser RA, Lang A, Investigators A. Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. *Movement disorders : official journal of the Movement Disorder Society* 2015;30:589-592.
172. Dafsari HS, Reddy P, Herchenbach C, et al. Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease. *Brain stimulation* 2016;9:78-85.
173. Pieper D, Mathes T. Survey of instructions for authors on how to report an update of a systematic review: guidance is needed. *Evid Based Med* 2017;22:45-48.
174. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. *Am Fam Physician* 2004;69:548-556.

175. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924-926.
176. Rochester MP, Kane AM, Linnebur SA, Fixen DR. Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence. *Ther Adv Drug Saf* 2018;9:297-308.
177. Administration USFaD. Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Repetitive Transcranial Magnetic Stimulation (rTMS) Systems. 2011; Last accessed: Nov. 2013.
178. Manolis TA, Manolis AA, Manolis AS. Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale. *Angiology* 2018:3319718780145.
179. Brasure M, Jutkowitz E, Fuchs E, et al. In: *Nonpharmacologic Interventions for Agitation and Aggression in Dementia*. Rockville (MD), 2016.